Axsome Therapeutics (AXSM) said Monday that its migraine drug Symbravo achieved the primary endpoint in a phase three trial, showing statistically significant improvements in overall quality of life and daily functioning compared with oral calcitonin gene-related peptide, or CGRP inhibitors, as measured by the Migraine-Specific Quality of Life Questionnaire.
The trial showed that 47.9% of patients achieved pain freedom within two hours with Symbravo compared with 1% on oral CGRP inhibitors, the company said. Additionally, 47.9% sustained pain relief from migraine for at least 24 hours with Symbravo versus 16.7% with CGRP inhibitors.
The trial also demonstrated that 51% of patients after treatment with Symbravo were able to resume normal activities quickly, compared to 11.5% on oral CGRP inhibitors, Axsome said.
Axsome said Symbravo was "well tolerated", with the most common adverse events being fatigue, nausea, vomiting, muscle tightness, and dizziness.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.